CORDIS
EU research results

CORDIS

English EN

The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals

Objective

A number of nanomedicine formulations have enabled, or been shown to hold considerable potential for enabling more effective and less toxic therapeutic interventions. However, progress to date in translating these initiatives to commercial success has been limited. One of the main reasons for this bottleneck is due to the inability of researchers and stakeholders to manufacture batches of the nanomedicine product at the required scale and according to Good Manufacturing Practice (GMP) requirements. The NANOFACTURING project will focus on
- facilitating access to required infrastructures and expertise
- creating GMP pilot lines for up-scaling manufacturing
- addressing the current developmental and production gaps
- taking nanomaterials already successfully produced at proof-of-concept/milligram levels and facilitating their scale-up to sub-kilogram quantities
- providing large-scale and GMP production for clinical trials and nanomedicine translation.
The NANOFACTURING project, through a consortium of 9 partners, will develop the synthetic processes, process control methods, analytical assays for QA/QC, functional specifications, and best practices, interfacing existing R&D centres of excellence, transfer organisations and private GMP manufacturing facilities (including SMEs) to ensure efficient translation from discovery through to first in man, proof-of-concept studies and beyond to Phase III according to industrial and regulatory standards. Specifically, the NANOFACTURING project aims to create a platform process for early, mid- and large-scale manufacturing of glycan-coated gold nanoparticles (GNPs), a widely researched and developed class of self-forming nanoparticles. The ability to engineer new nanopharmaceuticals based on this patent protected platform technology, developed by Midatech Biogune S.L. (Project Coordinator), will have inherent advantages over existing treatments for multiple therapeutic areas.

Coordinator

MIDATECH PHARMA ESPANA SL

Address

Parque Tecnologico De Bizkaia Edificio 800 2a Planta
48160 Derio

Spain

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 2 516 593,75

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

CENTRE FOR PROCESS INNOVATION LIMITED LBG

United Kingdom

EU Contribution

€ 2 080 420,50

PROCHIMIA SURFACES SP. Z O.O.

Poland

EU Contribution

€ 472 875

GALCHIMIA SA

Spain

EU Contribution

€ 675 553,75

MIDATECH LTD

United Kingdom

EU Contribution

€ 866 958,75

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 612 921

LGAI TECHNOLOGICAL CENTER SA

Spain

EU Contribution

€ 409 708,75

IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE

Italy

EU Contribution

€ 76 618,41

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland

"INSTITUTO TUMORI ""GIOVANNI PAOLO II"""

Italy

EU Contribution

€ 187 131,59

Project information

Grant agreement ID: 646364

Status

Closed project

  • Start date

    1 February 2015

  • End date

    31 January 2019

Funded under:

H2020-EU.2.1.2.1.

  • Overall budget:

    € 8 758 519,77

  • EU contribution

    € 7 898 781,50

Coordinated by:

MIDATECH PHARMA ESPANA SL

Spain

This project is featured in...